Form 8-K - Current report:
SEC Accession No. 0001013762-23-004548
Filing Date
2023-10-18
Accepted
2023-10-17 19:03:01
Documents
15
Period of Report
2023-10-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea186840-8k_inmunebio.htm   iXBRL 8-K 24654
2 PRESS RELEASE DATED OCTOBER 16, 2023 ea186840ex99-1_inmune.htm EX-99.1 9591
3 PRESS RELEASE DATED OCTOBER 17, 2023 ea186840ex99-2_inmune.htm EX-99.2 17011
7 GRAPHIC ex99-1_001.jpg GRAPHIC 1875
  Complete submission text file 0001013762-23-004548.txt   237332

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20231016.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20231016_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20231016_pre.xml EX-101.PRE 22361
9 EXTRACTED XBRL INSTANCE DOCUMENT ea186840-8k_inmunebio_htm.xml XML 3409
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 231330612
SIC: 2836 Biological Products, (No Diagnostic Substances)